Correlation Between SAB Biotherapeutics and Lexeo Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Lexeo Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Lexeo Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SAB Biotherapeutics and Lexeo Therapeutics, Common, you can compare the effects of market volatilities on SAB Biotherapeutics and Lexeo Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Lexeo Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Lexeo Therapeutics,.

Diversification Opportunities for SAB Biotherapeutics and Lexeo Therapeutics,

0.6
  Correlation Coefficient

Poor diversification

The 3 months correlation between SAB and Lexeo is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Lexeo Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lexeo Therapeutics, and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Lexeo Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lexeo Therapeutics, has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Lexeo Therapeutics, go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Lexeo Therapeutics,

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 2.37 times more return on investment than Lexeo Therapeutics,. However, SAB Biotherapeutics is 2.37 times more volatile than Lexeo Therapeutics, Common. It trades about 0.03 of its potential returns per unit of risk. Lexeo Therapeutics, Common is currently generating about -0.06 per unit of risk. If you would invest  8.00  in SAB Biotherapeutics on December 27, 2024 and sell it today you would lose (5.01) from holding SAB Biotherapeutics or give up 62.62% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy91.67%
ValuesDaily Returns

SAB Biotherapeutics  vs.  Lexeo Therapeutics, Common

 Performance 
       Timeline  
SAB Biotherapeutics 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Lexeo Therapeutics, 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Lexeo Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

SAB Biotherapeutics and Lexeo Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with SAB Biotherapeutics and Lexeo Therapeutics,

The main advantage of trading using opposite SAB Biotherapeutics and Lexeo Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Lexeo Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will offset losses from the drop in Lexeo Therapeutics,'s long position.
The idea behind SAB Biotherapeutics and Lexeo Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum